Drug
Otl 200
Otl 200: highest development phase Phase 3, developed by Orchard Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Orchard Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| OTL-200 NCT04283227 | Phase 3 | Lysosomal Storage Diseases |
Latest
No recent events.
Follow Otl 200 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.